Genetic events in the pathogenesis of multiple myeloma

Por Chng, W. J., Glebov, O., Bergsagel, P.L., Kuehl, W. M.
Publicado em 2007

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

Por Rosenthal, A, Luthi, J, Belohlavek, M, Kortüm, K M, Mookadam, F, Mayo, A, Fonseca, R, Bergsagel, P L, Reeder, C B, Mikhael, J R, Stewart, A K
Publicado no Blood Cancer J (2016)

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

Por Matthews, G M, Lefebure, M, Doyle, M A, Shortt, J, Ellul, J, Chesi, M, Banks, K-M, Vidacs, E, Faulkner, D, Atadja, P, Bergsagel, P L, Johnstone, R W
Publicado em 2013

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

Por Kortuem, K M, Braggio, E, Bruins, L, Barrio, S, Shi, C S, Zhu, Y X, Tibes, R, Viswanatha, D, Votruba, P, Ahmann, G, Fonseca, R, Jedlowski, P, Schlam, I, Kumar, S, Bergsagel, P L, Stewart, A K
Publicado no Blood Cancer J (2016)

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation

Por Roy, V, Stewart, A K, Bergsagel, P L, Dispenzieri, A, Laumann, K, Allred, J, Lacy, M Q, Fonseca, R, Reeder, C B, Kumar, S, Rivera, C E, Gertz, M A, Buadi, F K, Hayman, S R, Rajkumar, S V
Publicado no Blood Cancer J (2015)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

Por Ravi, P, Kumar, S, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R S, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado no Blood Cancer J (2017)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

Por Ravi, P, Kumar, S, Larsen, J T, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado no Blood Cancer J (2016)

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Por Pawlyn, C, Bright, M D, Buros, A F, Stein, C K, Walters, Z, Aronson, L I, Mirabella, F, Jones, J R, Kaiser, M F, Walker, B A, Jackson, G H, Clarke, P A, Bergsagel, P L, Workman, P, Chesi, M, Morgan, G J, Davies, F E
Publicado no Blood Cancer J (2017)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

Por Kumar, S K, LaPlant, B, Roy, V, Reeder, C B, Lacy, M Q, Gertz, M A, Laumann, K, Thompson, M A, Witzig, T E, Buadi, F K, Rivera, C E, Mikhael, J R, Bergsagel, P L, Kapoor, P, Hwa, L, Fonseca, R, Stewart, A K, Chanan-Khan, A, Rajkumar, S V, Dispenzieri, A
Publicado no Blood Cancer J (2015)